ALGOGram™, more and more popular!

Key numbers

Since the beginning of the year, the two ALGOGram™ sessions have encountered a great success.
Through the Spring and Summer sessions:

  • 31 slots have been booked
  • 10 studies have been performed
  • 6 new clients have experienced our unique in vivo screening tool
All the ANS Biotech team thanks you for your trust and your sustained confidence in our screening platform!

Beyond the boundaries…

Historically, most part of the test articles screened in ALGOGram™ were small molecules.

The fisrt semester 2021 was the great opportunity to challenge ALGOGram™ with other kinds of product: medical devices and natural extracts.

The results generated with these products are promising and really encouraging. We are eager to jump into the next step!

Our R&D efforts

A new pharmacological class has been tested in ALGOGram™ with a cannabinoid receptor agonist: WIN-55,212.

These preliminary results show that this compound has interesting effects in Neuropathic pain and Visceral pain.

 

Chronic pain is the most commonly cited reason for using medical cannabinoids and preclinical studies provide therapeutical strategies for treating pain in humans.

In preview…

The dates for the next ALGOGramTM Session are: 24SEPT2021-08OCT2021.

Without further delay, directly contact us should you want to register!